Aviz ȘCOALA DOCTORALĂ,
Prof.dr. Dana Pop
Director SD

Aviz IOSUD,
Prof.dr. Nadim Al Hajjar
Director CSUD

Fişa de verificare a îndeplinirii standardelor minimale
(valabilă pentru obţinerea atestatului de abilitare în Domeniul Medicină sau Domeniul Farmacie)

(în conformitate cu O.M. 6129/20.12.2016)

Candidat Bucșa Camelia Denisa

Nr. Crt.	Activi-tatea	Tipul activităţilor	Standarde minimale abilitare	Note asupra metodei de calcul	Gradul de îndeplinire
0	1	2	3	4	5
1.	Cercetare	**a. Articole *in extenso* in reviste cotate ISI Thomson Reuters (*articole în reviste cu factor de impact*) în calitate de autor principal**	minim 10 articole	În analiză vor fi incluse articole *in extenso* originale şi reviews. Autorul sau autorii principali ai unei publicaţii se consideră a fi oricare dintre următorii: a. Primul autor b. Autorul corespondent c. Alţi autori, a căror contribuţie este indicată explicit în cadrul publicaţiei a fi egală cu contribuţia primului autor sau a autorului corespondent d. Ultimul autor	16 articole CRITERIU ÎNDEPLINIT
		1. Bucsa, C; Frent, I; Stefan, R; Fodor, A; Inceu, G; Farcas, A; Rusu, A; Negovan, M; Mogosan, C. Adverse Drug Reactions to SGLT2i Reported by Type 2 Diabetes New Users: An Active Surveillance Study. PHARMACEUTICALS 18;6:-904 10.3390/ph18060904. doi:WOS:001514975300001(FI=4.8; 2025) https://www.webofscience.com/wos/woscc/full-record/WOS:001514975300001 2. Bucsa, C; Bruhs, D; Apan, A; Francu, E; Mogosan, C; Iaru, I. Drug utilization study of antiparkinsonian medication in Romania during 25 years. FRONTIERS IN PHARMACOLOGY 16;:-1534344 10.3389/fphar.2025.1534344. doi:WOS:001423989500001 (FI=4.8; 2025) https://www.webofscience.com/wos/woscc/full-record/WOS:001423989500001 3. Bucsa, C; Onea, M; Rusu, A; Farcas, A; Porojan, M; Dumitrascu, D; Iaru, I; Leucuta, D; Mogosan, C; Reeve, E; Moga, D. Translation, cultural adaptation and validation of the revised patients' attitudes towards deprescribing (rPATD) questionnaire in Romanian older adults. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY 19;111471:1479- 10.1016/j.sapharm.2023.07.011. doi:WOS:001079839600001 (FI=3.7; 2023) https://www.webofscience.com/wos/woscc/full-record/WOS:001079839600001 4. Iaru, I; Bucsa, C; Farcas, A; Pop, C; Cristina, A; Armean, S; Brumboiu, I; Vostinaru, O; Mogosan, C. Utilization of psychotropic medicines in Romania during 1998-2018. FRONTIERS IN PHARMACOLOGY 14;:-1157231 10.3389/fphar.2023.1157231. doi:WOS:000967897000001 (FI=4.4; 2023) https://www.webofscience.com/wos/woscc/full-record/WOS:000967897000001 5. Frent, I; Leucuta, D; Bucsa, C; Farcas, A; Casoinic, F; Mogosan, C. A Description of Acute Renal Failure and Nephrolithiasis Associated With Sodium-Glucose Co-Transporter 2 Inhibitor Use: A VigiBase Study. FRONTIERS IN PHARMACOLOGY 13;:-925805 10.3389/fphar.2022.925805. doi:WOS:000843329200001 (FI=5.6; 2022) https://www.webofscience.com/wos/woscc/full-record/WOS:000859084402377 6. Bucsa, C; Farcas, A; Udrea, M; Bojita, M; Mogosan, C; Leucuta, D. Concordance of pharmacist versus patient responses regarding counselling in community pharmacy. JOURNAL OF EVALUATION IN CLINICAL PRACTICE 28;4558:565- 10.1111/jep.13635. doi:WOS:000713937500001 (FI=2.336; 2022) https://www.webofscience.com/wos/woscc/full-record/WOS:000713937500001 7. Bucsa, C; Farcas, A; Iaru, I; Mogosan, C; Rusu, A. Drug utilisation study of antidiabetic medication during 2012-2019 in Romania. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 75;11:-e14770 10.1111/ijcp.14770. doi:WOS:000693726700001 (FI=3.149; 2021) https://www.webofscience.com/wos/woscc/full-record/WOS:000722870700068			

8. Frent, I; Bucsa, C; Leucuta, D; Farcas, A; Mogosan, C. An investigation on the association between sodium glucose co-transporter 2 inhibitors use and acute pancreatitis: A VigiBase study. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30;101428:1440- 10.1002/pds.5313. doi:WOS:000667916300001 (FI=2.732; 2021)
https://www.webofscience.com/wos/woscc/full-record/WOS:000667916300001

9. Farcas, A; Bucsa, C; Crisan, A; Cazacu, I; Leucuta, D; Mogosan, C. KNOWLEDGE, OPINION AND ATTITUDES TOWARDS ADVERSE DRUG REACTIONS REPORTING AMONG PHARMACY STUDENTS IN ROMANIA. FARMACIA 69;3602:608- 10.31925/farmacia.2021.3.24. doi:WOS:000667509000024.(FI=1.55; 2021)
https://www.webofscience.com/wos/woscc/full-record/WOS:000667509000024

10. Farcas, A; Balcescu, T; Anghel, L; Bucsa, C; Mogosan, C. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012. EXPERT OPINION ON DRUG SAFETY 19;6755:762- 10.1080/14740338.2020.1744561. doi:WOS:000550961800010 (FI=4.25; 2020)
https://www.webofscience.com/wos/woscc/full-record/WOS:000550961800010

11. Bucsa, C; Bulik, N; Farcas, A; Muresan, S; Muresan, I; Oniga, O. ADVERSE EVENTS FOLLOWING MEASLES-MUMPS-RUBELLA VACCINATION. A PROSPECTIVE OBSERVATIONAL STUDY. FARMACIA 68;2219:224-10.31925/farmacia.2020.2.5. doi:WOS:000527105400005 (FI=1.433; 2020)
https://www.webofscience.com/wos/woscc/full-record/WOS:000527105400005

12. Bulik, NB; Bucsa, C; Leucuta, D; Farcas, A; Cristina, A; Muresan, S; Muresan, I; Oniga, O. REACTOGENICITY AND MEDICALLY ATTENDED ADVERSE EVENTS FOLLOWING HEXAVALENT VACCINATION: AN OBSERVATIONAL PROSPECTIVE STUDY. FARMACIA 67;61018:1024- 10.31925/farmacia.2019.6.12. doi:WOS:000510208600012 (FI=1.607; 2019)
https://www.webofscience.com/wos/woscc/full-record/WOS:000510208600012

13. Bucsa, C; Moga, DC; Farcas, A; Mogosan, C; Dumitrascu, DL. An investigation of the concomitant use of angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs and diuretics. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 19;152938:2944- . doi:WOS:000359304500028 (FI=1.575; 2015)
https://www.webofscience.com/wos/woscc/full-record/WOS:000359304500028

14. Iancu, M; Bucsa, C; Farcas, A; Leucuta, D; Dincu, A; Mogosan, C; Dumitrascu, DL; Bojita, M. PATIENT'S COUNSELLING AND MANAGEMENT OF ADVERSE DRUG REACTIONS AND DRUG INTERACTIONS IN THE COMMUNITY PHARMACY. FARMACIA 63;180:85- . doi:WOS:000349742300013 (FI=1.162; 2015)
https://www.webofscience.com/wos/woscc/full-record/WOS:000349742300013

15. Bucsa, C; Farcas, A; Cazacu, I; Leucuta, D; Achimas-Cadariu, A; Mogosan, C; Bojita, M. How many potential drug-drug interactions cause adverse drug reactions in hospitalized patients?. EUROPEAN JOURNAL OF INTERNAL MEDICINE 24;127:33- 10.1016/j.ejim.2012.09.011. doi:WOS:000312831000015 (FI=2.3; 2013)
https://www.webofscience.com/wos/woscc/full-record/WOS:000312831000015

16. Bucsa, CD; Cazacu, I; Farcas, AM. THE PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS IN THE THERAPY OF ROMANIAN COMMUNITY PHARMACY'S PATIENTS. FARMACIA 60;4510:516- . doi:WOS:000307493600006 (FI=0.578; 2012)
https://www.webofscience.com/wos/woscc/full-record/WOS:000307493600006

b. (ISI) Factor cumulat de Impact autor principal (FCIAP)	minim 10	O revistă cotată ISI este o revistă pentru care Thomson Reuters calculează şi publică factorul de impact în „Journal Citation Reports”. Factorul cumulat de Impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP=suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI)	45.972 CRITERIU ÎNDEPLINIT
c. Articole *in extenso* in reviste cotate ISI Thomson Reuters în calitate de coautor	minim 5 articole		20 articole CRITERIU ÎNDEPLINIT

1. Andersen, J; Talarico, R; Marinello, D; Aguilera, S; Galetti, I; Bandeira, M; Castan, JB; Blagojevic, J; Bouillot, C; Bucsa, C; Cannizzo, S; Cavagna, L; Ciupera, M; Collado, E; Cornet, A; Damian, L; Diederichsen, L; Drapalova, O; Elefante, E; Farrington, S; Frank, C; Gaglioti, A; Guiducci, S; Guimaraes, V; Luciu, R; Matthews, L; Moroncini, G; Olesinska, M; Patsalias, A; Peene, I; Piantoni, S; Pizzorni, C; Paolino, S; Pha, M; Pamfil, C; Scheerhoorn-Pullen, J; Schlüter, S; Scrivo, R; Sciascia, S; Testoni, M; Vieira, A; Cutolo, M; Burmester, G; Mosca, M. Patient partnership model in rare and complex rheumatological conditions: research and beyond in European Reference Network ReCONNET. LANCET RHEUMATOLOGY 8;4e311:e319- 10.1016/S2665-9913(25)00284-X. doi:WOS:001730484600009.. (FI=16.4; 2026)
https://www.webofscience.com/wos/woscc/full-record/WOS:001730484600009

2. Bandeira, M; Marinello, D; Barreira, SC; Richter, JG; de Vries-Bouwstra, JK; Lundberg, IE; Pamfil, C; Cornet, A; Mosca, M; Rath, A; Triggiani, M; Simonini, G; Ferraris, A; Solecka, W; Lanzillotta, M; Regola, F; Vencovsky, J;

Sobanski, V; Bucsa, C; Tsang-A-Sjoe, M; Závada, J; Del Papa, N; Brkic, Z; Hunzelmann, N; Haase, I; Frank, C; Smith, V; Talarico, R; Fonseca, JE; Schneider, M. Coding systems and monitoring practices across the ERN ReCONNET: insights from a comprehensive survey and unmet needs. ORPHANET JOURNAL OF RARE DISEASES 21;1:-186 10.1186/s13023-026-04304-7. doi:WOS:001760967000001.. (FI=3.5; 2026)
https://www.webofscience.com/wos/woscc/full-record/WOS:001760967000001

3. Mertz, P; Sander, O; Faria, R; Crisafulli, F; Silva-Ribeiro, S; Kawka, L; Sztejkowski, C; Düsing, C; Rose, T; Lamas, A; Vasconcelos, C; Fontana, G; Semeraro, P; Neagu, T; Resteu, M; Damian, L; Pamfil, C; Bucsa, C; Matthews, LJ; Devilliers, H; Rednic, S; Arnaud, L. Identifying quality of life domains and facets affected in relapsing polychondritis: a qualitative analysis for the development of a disease-specific health-related quality of life instrument. ORPHANET JOURNAL OF RARE DISEASES 21;1:-157 10.1186/s13023-026-04297-3. doi:WOS:001742573500001.. (FI=3.5; 2026)
https://www.webofscience.com/wos/woscc/full-record/WOS:001742573500001

4. Arnaud, L; Sander, O; Rednic, S; Mertz, P; Faria, R; Crisafulli, F; Silva-Ribeiro, S; Kawka, L; Sztejkowski, C; Düsing, C; Rose, T; Lamas, A; Vasconcelos, C; Fontana, G; Semeraro, P; Neagu, T; Resteu, M; Damian, L; Pamfil, C; Bucsa, C; Matthews, LJ; Talarico, R; Mosca, M; Turchetti, G; Thibault, T; Devilliers, H. European Reference Network (ERN) ReCONNET methodology for the cross-cultural adaptation of instruments for research and care in the context of rare connective tissue diseases (CROSSADAPT). ORPHANET JOURNAL OF RARE DISEASES 20;1:-230 10.1186/s13023-025-03674-8. doi:WOS:001489457200002.. (FI=3.5; 2025)
https://www.webofscience.com/wos/woscc/full-record/WOS:001489457200002

5. Ahmadizar, F; Luxi, N; Raethke, M; Schmikli, S; Riefolo, F; Saraswati, PW; Bucsa, C; Osman, A; Liddiard, M; Maques, FB; Petrelli, G; Sonderlichova, S; Thurin, N; Villalobos, F; Trifiro, G; Sturkenboom, M. Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials. DRUG SAFETY 46;6575:585- 10.1007/s40264-023-01304-5. doi:WOS:000980137800002.. (FI=4; 2023)
https://www.webofscience.com/wos/woscc/full-record/WOS:000980137800002

6. Bulik, NB; Farcas, A; Bucsa, C; Iaru, I; Oniga, O. Safety of Antibiotics in Hospitalized Children in Romania: A Prospective Observational Study. PHARMACEUTICALS 15;6:-713 10.3390/ph15060713. doi:WOS:000816583500001.. (FI=4.6; 2022)
https://www.webofscience.com/wos/woscc/full-record/WOS:000816583500001

7. Huruba, M; Farcas, A; Leucuta, DC; Bucsa, C; Mogosan, C. A VigiBase Descriptive Study of Fluoroquinolone-Associated Peripheral Nervous System Disorders. PHARMACEUTICALS 15;2:-143 10.3390/ph15020143. doi:WOS:000825147300001.. (FI=4.6; 2022)
https://www.webofscience.com/wos/woscc/full-record/WOS:000825147300001

8. Ismaiel, A; Bucsa, C; Farcas, A; Leucuta, DC; Popa, SL; Dumitrascu, DL. Effects of Branched-Chain Amino Acids on Parameters Evaluating Sarcopenia in Liver Cirrhosis: Systematic Review and Meta-Analysis. FRONTIERS IN NUTRITION 9;:-749969 10.3389/fnut.2022.749969. doi:WOS:000753650800001.. (FI=5; 2022)
https://www.webofscience.com/wos/woscc/full-record/WOS:000753650800001

9. Damian, L; Pamfil, C; Bucsa, C; Nicula, C; Mouthon, L; Amoura, Z; Cutolo, M; Burmester, GR; Fonseca, JE; Grapini, L; Arnaud, L; Rednic, S. Rare within rare. Necrotising scleritis and peripheral ulcerative keratitis: eye-threatening complications of relapsing polychondritis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 40;5S86:S92- . doi:WOS:000799906400012.. (FI=3.7; 2022)
https://www.webofscience.com/wos/woscc/full-record/WOS:000799906400012

10. Huruba, M; Farcas, A; Leucuta, DC; Bucsa, C; Sipos, M; Mogosan, C. A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders. SCIENTIFIC REPORTS 11;1:-14375 10.1038/s41598-021-93763-y. doi:WOS:000675273800014.. (FI=4.997; 2021)
https://www.webofscience.com/wos/woscc/full-record/WOS:000675273800014

11. Sipos, M; Farcas, A; Leucuta, DC; Bucsa, C; Huruba, M; Mogosan, C. Second-Generation Cephalosporins-Associated Drug-Induced Liver Disease: A Study in VigiBase with a Focus on the Elderly. PHARMACEUTICALS 14;5:-441 10.3390/ph14050441. doi:WOS:000654388800001.. (FI=5.215; 2021)
https://www.webofscience.com/wos/woscc/full-record/WOS:000654388800001

12. Bala, CG; Rusu, A; Ciobanu, D; Bucsa, C; Roman, G. Amino Acid Signature of Oxidative Stress in Patients with Type 2 Diabetes: Targeted Exploratory Metabolomic Research. ANTIOXIDANTS 10;4:-610 10.3390/antiox10040610. doi:WOS:000642749000001.. (FI=7.675; 2021)
https://www.webofscience.com/wos/woscc/full-record/WOS:000642749000001

13. Cazacu, I; Stroe, R; Dondera, R; Apan, B; Farcas, A; Cristina, A; Bucsa, C; Mogosan, C. Safety Profile of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Hepatitis C in Romania: an Analysis Conducted in VigiBase®/WHO. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES 29;4603:610- 10.15403/jgld-2889. doi:WOS:000598486100020.. (FI=2.008; 2020)
https://www.webofscience.com/wos/woscc/full-record/WOS:000598486100020

14. Bulik, NB; Bucsa, C; Farcas, A; Oniga, O. HEXAVALENT VACCINE IN EUROPE: SAFETY DATA FROM THE RANDOMIZED CLINICAL TRIALS. FARMACIA 66;5747:757- 10.31925/farmacia.2018.5.2. doi:WOS:000447181100002.. (FI=1.527; 2018)
https://www.webofscience.com/wos/woscc/full-record/WOS:000447181100002

15. Farcas, A; Popa, AD; Mardale, S; Bucsa, C; Leucuta, DC; Mogosan, C. COUNSELLING, KNOWLEDGE AND ATTITUDES TOWARDS COMBINED ORAL CONTRACEPTIVES: A CROSS-SECTIONAL SURVEY AMONG ROMANIAN WOMEN. FARMACIA 65;6954:961- . doi:WOS:000429425600001.. (FI=1.507; 2017)
https://www.webofscience.com/wos/woscc/full-record/WOS:000429425600001

16. Farcas, A; Leucuta, D; Bucsa, C; Mogosan, C; Dumitrascu, D. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY

38;61390:1397- 10.1007/s11096-016-0378-2. doi:WOS:000389302300009.. (FI=1.555; 2016)
https://www.webofscience.com/wos/woscc/full-record/WOS:000389302300009

17. Farcas, A; Gligor, F; Bucsa, C; Mogosan, C; Bojita, M; Dumitrascu, D. THE CURRENT INSIGHT ON DUAL RENIN-ANGIOTENSIN SYSTEM BLOCKADE: A DATA REVIEW WITH A FOCUS ON SAFETY. FARMACIA 63;3325:333- . doi:WOS:000356637300001.. (FI=1.162; 2015)
https://www.webofscience.com/wos/woscc/full-record/WOS:000356637300001

18. Farcas, A; Bucsa, C; Sinpetrean, A; Leucuta, D; Mogosan, C; Dumitrascu, D; Achimas, AC; Bojita, M. Preventability analysis of adverse drug reactions detected in two internal medicine departments in Romania. INTERNAL AND EMERGENCY MEDICINE 9;2187:193- 10.1007/s11739-012-0843-4. doi:WOS:000336422000012.. (FI=2.624; 2014)
https://www.webofscience.com/wos/woscc/full-record/WOS:000336422000012

19. Pop, C; Farcas, AM; Leucuta, DC; Bucsa, C; Faraian, D; Florea, DR; Tatulescu, D; Bojita, MT. MONITORING ADVERSE REACTIONS OF THE CANTGRIP® VACCINE. FARMACIA 60;6798:808- . doi:WOS:000315931200004.. (FI=0.578; 2012)
https://www.webofscience.com/wos/woscc/full-record/WOS:000315931200004

20. Farcas, AM; Farah, C; Bojita, MT. PATIENTS REPORTING OF SUSPECTED ADVERSE REACTIONS TO ANTIDEPRESSANTS. A PILOT METHODOLOGICAL STUDY. FARMACIA 58;3255:263- . doi:WOS:000279150100003.. (FI=0.85; 2010)
https://www.webofscience.com/wos/woscc/full-record/WOS:000279150100003

d. Index Hirsch	minim 6	Va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science, Core Collection, Thomson Reuters	10 CRITERIU ÎNDEPLINIT



Cluj – Napoca,

10.06.2026.